GLP-1 Agonists - How to be the next Keytruda?
???????????? ????????????
"?????????????????? ?????????????????? ???????????????? ?????????????? ?????????????????????? ???????????????????????? | ?????????????? ???????? & ?????? ???????????????? ???????????????????? | ??????'?? ???????????????"
????????-????-?????????? ???????????? ??????????-????-?????????? -?????????????????????????????? ?????? ???????????? ?? ??????-1 ?????????????? ?? ????????????????
??????????????????? is considered a ????????-????-?????????? ????-1 ?????????????????? ?????? ?????????? based on its impressive clinical trial results, including overall survival and response rates, leaving behind ????????????, ?????????? ?????? ?????? ??????????-???? ?????????? ????1 ??????????????????, which leaves some cues for GLP-1 agonist pharma companies, to take a cue from
???Similarly even though ?????????????? (liraglutide) was the First-in-class GLP-1 agonist with limited weight loss, ???????????? (semaglutide) has proven its potential to be best-in-class by showing a six-percentage point greater weight loss effect than liraglutide (13.8 vs 7.8%), which has reinforced that products that come later have a chance to become better, if they continuously work on their innovation aspect
???In the crowded GLP-1 agonists' landscape, differentiation of products from different companies, is not very conspicuous, as most products have joined the GLP-1 agonists' bandwagon, with a hope to make a fast buck
???While working on the GLP-1 MOA may get these companies a piece of the GLP-1 market, The companies who are working on ?????? ?????????????????????????????? ???????? ?????? ?????? ?????????? ?????? ???????????? ???? ?????????????? ?????? ?????????? ?????? ?????? ???????? ???? ?????? ???????????????????? ?????? ???????????? ???????????? ??????????????
???Unless there are differentiators that will help brand ambassadors, a 4th GLP-1 Agonist won't be able to make a big mark
?????????????????????????? ??????????????????????: The Key differentiators that can be used to guide proper innovation strategy include Dosing considerations (Injectable versus Oral), Clinical efficacy versus adverse effects, Effective Reimbursement strategy, Drug adherence to name a few..
Curious to know more about which differentiating factors can make your GLP-1 agonist Best-in-class, please send a message -Our upcoming report GLP-1 Agonists Landscape 2.0- The Perspective addresses the same. If you like this post, please like, share and repost????!